A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV.

Trial Profile

A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 24 Apr 2018 Planned primary completion date changed from 31 Dec 2020 to 1 Dec 2020.
    • 21 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Dec 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top